Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carrie Long

Nurse Practitioner, Psychiatric/Mental Health Bedford, IN Nurse Practitioner

NPI 1619323623 CMS profile 10842172

2125 16Th St, Bedford, IN 47421

Open in the dashboard

General payments

$5,749

348 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carrie Long of Bedford, IN is reported in the CMS Open Payments database as having received $5,749 across 348 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,646 89
2024 General $1,064 62
2023 General $1,045 71
2022 General $993 63
2021 General $1,002 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Long
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Carrie Long were reported at $1,646. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Carrie Long Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,002 $166 $54–$482 $132
2022 $993 $195 $66–$559 $149
2023 $1,045 $233 $82–$673 $160
2024 $1,064 $236 $84–$688 $164
2025 $1,646 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $998 66 payments
  2. AbbVie, Inc. $766 56 payments
  3. Otsuka America Pharmaceutical, Inc. $715 38 payments
  4. Alkermes, Inc. $638 38 payments
  5. Lundbeck LLC $419 23 payments
  6. Teva Pharmaceuticals USA, Inc. $384 19 payments
  7. Vanda Pharmaceuticals Inc. $284 12 payments
  8. Sunovion Pharmaceuticals Inc. $198 13 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $187 11 payments
  10. Axsome Therapeutics, Inc. $187 10 payments
  11. Other $973 62 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,623 344 payments
  2. Education $126 4 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA $819 56 payments
  2. REXULTI Psychiatry $606 33 payments
  3. LYBALVI $596 35 payments
  4. ARISTADA Cns $553 32 payments
  5. ARISTADA Cns $553 32 payments
  6. VRAYLAR Neuroscience $480 40 payments
  7. REXULTI Psychiatry $419 23 payments
  8. ARISTADA Cns $352 21 payments
  9. ARISTADA Cns $352 21 payments
  10. VRAYLAR Neuroscience $286 16 payments
  11. Other $3,130 178 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,385

Median for Nurse Practitioner: 389

Drug cost

$464,522

Median for Nurse Practitioner: $21,885

Branded share of claims

22.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 85 $136,578
Ingrezza Valbenazine Tosylate Brand 12 $95,128
Vraylar Cariprazine Hcl Brand 44 $80,288
Spravato Esketamine Hcl Brand 25 $29,548
Trintellix Vortioxetine Hydrobromide Brand 29 $27,173
Auvelity Dextromethorphan Hbr/Bupropion Brand 19 $20,683
Topiramate Generic 20 $9,067
Lurasidone Hcl Generic 27 $6,529
Vyvanse Lisdexamfetamine Dimesylate Brand 16 $6,083
Quetiapine Fumarate Generic 184 $5,863

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$10,475

Medicare's payments for the services billed

Medicare patients

52

Average age 56

Services billed

217

37 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 65%
High blood pressure 48%
Arthritis 48%
Diabetes 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $148
  • Lundbeck LLC $92
$241 85 —
CAPLYTA
  • ITI, Inc. $238
$238 — —
Auvelity
  • Axsome Therapeutics, Inc. $100
$100 19 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $91
$91 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record